CRA’s Rare Disease Spotlight team is excited to present Project LEOPARD, an ongoing assessment of the long-term evolution and outlook for patient access in rare disease. In this first installment, Cécile Matthews and Bhavesh Patel explore what we can expect for patient access in established, or competitive, rare diseases, and how life sciences companies can successfully navigate the future environment for this category of rare disease. Learn more about Project LEOPARD and subscribe to our rare disease insights.
Beyond the single asset: The rise of combination and synergistic innovation in neurology drug development
Introduction Historically, drug development within the neurology space has been characterized by the search for individual therapies that can arrest complex...